This week, once again, companies across the biotech sector continued to re-evaluate their pipelines and trim their workforces in a bid to conserve cash and extend their financial runway. Meanwhile, the regulatory landscape saw positive momentum with both new drug approvals and expanded indications. Against a backdrop of growing attention on monkeypox, Siga Technologies' Mpox vaccine candidate failed to impress in a clinical trial. Nevertheless, the company maintains a positive outlook regarding the treatment's future potential.
Let's dive into the details.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com